Franklin Biolabs Company Profile

Background

Franklin Biolabs, established in October 2024, is a genetic medicines-focused Contract Research Organization (CRO) headquartered in Philadelphia, Pennsylvania. The company was founded by Dr. James M. Wilson, a pioneer in gene therapy, with the mission to provide comprehensive solutions from discovery to commercialization for the global genetic medicines industry. Franklin Biolabs aims to bridge the gap between groundbreaking research and the delivery of transformative therapies to patients with severe and disabling diseases.

Key Strategic Focus

Franklin Biolabs specializes in accelerating the development of advanced cell and gene therapies. The company's core objectives include:

Preclinical and Translational Research: Offering services such as pharmacology, toxicology, pharmacokinetics, and both GLP and non-GLP studies to support the transition from discovery to clinical trials.

Vector Production and Analytics: Providing full-service AAV vector production, process development, large-scale manufacturing, and analytical testing to ensure the quality and scalability of gene therapy vectors.

Bioanalytical Services: Conducting immunogenicity assessments, biodistribution studies, viral shedding analyses, and biomarker evaluations to characterize drug products and ensure their safety and efficacy.

The company leverages cutting-edge technologies and scientific methodologies to support biotech, pharmaceutical, and academic institutions worldwide.

Financials and Funding

Franklin Biolabs is backed by Savanne Life Sciences, the investment arm of Mauritius-based Bioculture Group. This strategic investment underscores international interest and demand for gene therapy innovation. The funding is intended to support the development of genetic medicines by providing access to critical research services and accelerating the path from discovery to commercialization.

Pipeline Development

As a CRO, Franklin Biolabs does not have its own therapeutic pipeline but collaborates with clients to advance their gene therapy candidates. The company's services are designed to expedite the development process, aiming to transition candidates to Investigational New Drug (IND) applications within 18 to 24 months.

Technological Platform and Innovation

Franklin Biolabs distinguishes itself through several proprietary technologies and scientific methodologies:

AAV Vector Production: Expertise in designing, characterizing, and optimizing adeno-associated virus (AAV) vectors, which are critical for gene therapy applications.

Advanced Analytical Testing: Utilizing cutting-edge technologies for comprehensive characterization of drug products and substances, ensuring they meet the highest quality and safety standards.

Bioanalytical Platforms: Employing advanced platforms such as Mass Spectrometry, ELISA, and Meso Scale Discovery (MSD) for sensitive, quantitative analysis of biomarkers and protein expression.

Leadership Team

Dr. James M. Wilson: Founder and Executive Chair. Dr. Wilson has nearly 40 years of experience in gene therapy, having previously led the Gene Therapy Program at the University of Pennsylvania. His laboratory discovered a family of adeno-associated viruses (AAV) that have become the technology platform of choice in gene therapy.

Dr. Vatsala Naageshwaran: Appointed as CEO in 2025. Dr. Naageshwaran brings extensive experience in the biotech industry, focusing on strategic growth and operational excellence.

Mehul Bhatt: Board Member representing Savanne Life Sciences. Mr. Bhatt has a background in strategic leadership and sustainable development, with experience in various international organizations.

Jacob Griffiths: Board Member representing Bioculture Group. Mr. Griffiths has experience in conservation-focused NGOs and has been involved with Bioculture Group in legal and business strategy roles.

Howard D. Palefsky: Board Member from Victoria Capital Management. Mr. Palefsky has extensive experience in the life sciences, healthcare, and medical technology industries, having led organizations to significant growth and value creation.

Dr. Eckart W. Schwarz: Board Member from Quantocks Consulting. Dr. Schwarz is a seasoned pharmaceutical executive with over 30 years of experience in global strategic initiatives and drug development.

Dr. Annalisa Jenkins: Board Member from Genomics England. Dr. Jenkins is a biopharma thought leader with over 25 years of industry experience, focusing on building and financing biotech companies addressing rare diseases.

Leadership Changes

In 2025, Dr. Vatsala Naageshwaran was appointed as CEO of Franklin Biolabs, succeeding Dr. James M. Wilson, who transitioned to the role of Executive Chair.

Competitor Profile

Market Insights and Dynamics

The global gene therapy market is experiencing significant growth, driven by advancements in genetic research, increasing prevalence of genetic disorders, and rising investments in biotechnology. The market is characterized by rapid innovation, with numerous companies developing novel therapies and supporting technologies.

Competitor Analysis

Key competitors in the gene therapy CRO space include:

New England Biolabs (NEB): An American life sciences company specializing in the production and supply of recombinant and native enzyme reagents for life science research. NEB also provides products and services supporting genome editing, synthetic biology, and next-generation sequencing.

Charles River Laboratories: A full-service CRO offering preclinical and clinical laboratory services for the pharmaceutical, medical device, and biotechnology industries.

WuXi AppTec: A global company providing a broad range of services in the pharmaceutical, biotechnology, and medical device industries, including drug discovery, development, and manufacturing.

Strategic Collaborations and Partnerships

Franklin Biolabs collaborates with various biotech, pharmaceutical, and academic institutions to advance genetic medicine research and development. The company's partnership with Savanne Life Sciences provides strategic investment and support, enabling Franklin Biolabs to expand its services and global reach.

Operational Insights

Franklin Biolabs differentiates itself through its comprehensive suite of services, deep expertise in AAV-based gene therapies, and commitment to quality and innovation. The company's integrated approach, from vector production to bioanalytical services, offers clients a seamless path from discovery to commercialization.

Strategic Opportunities and Future Directions

Franklin Biolabs aims to become the leading provider of comprehensive genetic medicine solutions, including worldwide clinical development. The company plans to leverage its bench-to-bedside expertise to expand its platform of services, supporting the global genetic medicines industry in bringing transformative therapies to patients.

Contact Information

For more information, visit Franklin Biolabs' official website.

Please note that specific contact details such as email addresses and phone numbers are not provided in this profile.